Clinical Data Launches Pain Research Services
Clinical Data, Inc. (NASDAQ: CLDA) announced today the launch of its pain research genotyping service by its Cogenics™ Division. Cogenics developed the proprietary genotyping service called the Pain Research Panel, which enables the investigation of key target genes involved in pain as well as those that mediate the therapeutic effects of pharmacological agents used to treat pain, inflammation, and mood conditions.
The Pain Research Panel is based on a custom Affymetrix® microarray made available through an agreement with Algynomics Inc and contains more than 3,000 SNPs representing 350 genes implicated in pain perception, inflammation, and mood.
Robert Bondaryk, Ph.D., Senior Vice President and General Manager of Cogenics said, “Not only does the panel revolutionize the approach to pain research, but researchers benefit immediately from Cogenics’ and Algynomics’ expertise and speed of results without the requirement to set-up and learn how to run these analyses and technologies themselves. This kind of outsourcing allows researchers to focus on the scientific meaning of their results.”
William Maixner DDS, Ph.D., President of Algynomics said, “We have designed the Pain Research Panel for use in research studies seeking to identify the genetic contribution to pain susceptibility and to examine positive and adverse responses to therapeutic regimens for acute and chronic pain.”
Luda Diatchenko, MD, Ph.D., Chief Scientific Officer of Algynomics further added, “We anticipate this proprietary panel becoming a standard tool for clinical scientists and researchers to better understand the pathophysiology of pain conditions and the identification of valuable, clinical biomarkers.”
The size of the pain therapeutics market has been estimated to be approximately $31 billion in 2005 with projected annual growth of 9 percent per year through 2010. (D&MD Publications, “Pain Therapeutics” Report 7/1/2006)
For more information on Cogenics’ Pain Research Panel services, please call (919) 469-7682 or email jlovgren@cogenics.com
About Cogenics
Cogenics offers 18 years of experience as a trusted provider of the broadest range of pharmacogenomics and molecular biology services available globally. Cogenics provides integrated services for nucleic acid extraction, genotyping, sequencing, QPCR, and gene expression, as well as offering biorepository and biobanking services, for both research and regulated environments: GLP, cGMP and CLIA. Cogenics combines operations from the acquisitions of Genaissance Pharmaceuticals, Lark Technologies (US & UK), Icoria, and Genome Express (France). Its customers include some of the world’s most respected pharmaceutical and biotechnology companies, agencies of the US National Institutes of Health, leading government and academic researchers in the international life science community, and major agricultural companies and agencies. Visit the company’s website at www.cognenics.com.
About Clinical Data, Inc.
Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, from targeted science to better healthcare. Its PGxHealth division focuses on genetic test and biomarker development to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics division provides molecular and pharmacogenomics services to both research and regulated environments. Its Vital Diagnostics division offers in vitro diagnostics solutions for the clinical laboratory. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide. Visit the company’s website at www.clda.com for more information.
About Algynomics, Inc
Algynomics (www.algynomics.com) is a privately held company that was founded in 2005. The core goal of Algynomics is to become the world-wide leader in the area of pain diagnostics, management, and prevention by use of emerging methodologies with an emphasis in the field of pain genomics. Algynomics holds a lead position in the area of human pain genetics and owns the rights, which are licensed from the University of North Carolina at Chapel Hill, to develop and market genetic markers in the field of pain. The company is developing niche specific medical devices utilizing proprietary software programs that integrate information of genetic pain biomarkers with neurological and psychological assessments which will permit the sub-diagnosis and “tailoring” of safe and effective pain therapies for the individual patient. The introduction of these devices to clinical practice will reduce overall healthcare costs for payers, providers and patients and will ultimately become a key diagnostic device for healthcare providers. Algynomics also holds the rights to develop and market several novel small molecular weight compounds as analgesics based on its discoveries in the area of pain genomics. Algynomics is exploring further partnership opportunities targeting diagnostic and therapeutic areas in pain management
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as “expect(s),”"feel(s),”"believe(s),”"will,”"may,”"anticipate(s)” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to statements regarding: our ability to successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: whether our products will gain wide acceptance in the market; the extent to which genetic markers (haplotypes) are predictive of clinical outcomes and drug efficacy and safety; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for pharmacogenetic and biomarker products and services; general economic downturns; and other risks contained in our various SEC reports and filings, including but not limited to our Annual Report on Form 10-K for the fiscal year ended March 31, 2007, our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2007, and our Current Reports on Form 8-K filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.